Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
Allergy2021Vol. 77(1), pp. 186–196
Citations Over TimeTop 1% of 2021 papers
Shigeharu Fujieda, Shoji Matsune, Sachio Takeno, Nobuo Ohta, Mikiya Asako, Claus Bachert, Tomoyuki Inoue, Yoshinori Takahashi, Hiroyuki Fujita, Yamo Deniz, Paul Rowe, Benjamin Ortiz, Yongtao Li, Leda Mannent
Abstract
Dupilumab produced consistent improvement in symptoms of severe CRSwNP irrespective of ECRS status. Therefore, blood eosinophil level may not be a suitable biomarker for dupilumab efficacy in CRSwNP.
Related Papers
- → Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps(2021)94 cited
- → Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps(2021)19 cited
- → Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab(2024)2 cited
- → Screening olfaction under dupilumab in chronic rhinosinusitis with nasal polyps(2024)3 cited
- → Republication de : Dupilumab in pediatric severe chronic rhinosinusitis with nasal polyps and asthma(2024)